For Theravance, A Big Year Gets Off To A Strong Start

Theravance could soon have its first substantial revenue generator on the market, the COPD therapy Breo Ellipta partnered with GlaxoSmithKline. The launch of Breo is just one of several catalysts expected to unfold for the biotech in 2013.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet